ENTREMED, INC. (NASDAQ:ENMD)

CAPS Rating: No stars

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.

Recs

2
Player Avatar ShuntSD (96.28) Submitted: 10/20/2006 2:37:38 PM : Outperform Start Price: $22.55 ENMD Score: -136.41

As others say, a gamble with huge upside. But the small molecule research is promising and acquisition was a nice move. Keep close eye on it with stops.

Featured Broker Partners


Advertisement